康泰医学
(300869)
| 流通市值：41.76亿 | | | 总市值：66.70亿 |
| 流通股本：2.52亿 | | | 总股本：4.02亿 |
| 报告期 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 211,789,804.52 | 99,175,164.46 | 746,902,140.39 | 617,227,119.11 |
| 营业收入 | 211,789,804.52 | 99,175,164.46 | 746,902,140.39 | 617,227,119.11 |
| 二、营业总成本 | 212,974,691.76 | 102,176,199.13 | 568,889,907.42 | 429,154,337.97 |
| 营业成本 | 106,962,931.79 | 50,192,307.62 | 316,821,601.08 | 258,236,909.02 |
| 税金及附加 | 4,532,617.97 | 2,799,974.12 | 12,853,512.08 | 10,975,002.66 |
| 销售费用 | 36,429,656.3 | 16,173,587.84 | 117,690,546.98 | 79,095,263.26 |
| 管理费用 | 17,826,736.72 | 10,796,696.87 | 41,778,164.98 | 32,395,396.77 |
| 研发费用 | 56,055,044.05 | 27,140,047.87 | 110,600,251.24 | 79,806,439.64 |
| 财务费用 | -8,832,295.07 | -4,926,415.19 | -30,854,168.94 | -31,354,673.38 |
| 其中:利息费用 | - | - | 45,103,342.44 | - |
| 其中:利息收入 | - | - | 81,178,482.31 | - |
| 加:公允价值变动收益 | 1,548,798.82 | 562,915.78 | 2,023,602.74 | -46,578,258.52 |
| 加:投资收益 | 11,098,894.68 | 7,695,776.25 | 11,468,491.81 | 57,106,608.77 |
| 资产处置收益 | 7,936.7 | -28,003.62 | -67,801.93 | -5,635.27 |
| 资产减值损失(新) | -6,129,554.46 | -3,190,081.7 | -39,110,548.5 | -8,493,410.76 |
| 信用减值损失(新) | -1,418,946.35 | -670,641.33 | 1,080,618.72 | 333,740.17 |
| 其他收益 | 3,984,036.36 | 1,438,713.74 | 33,327,457.41 | 29,903,988.33 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 7,906,278.51 | 2,807,644.45 | 186,734,053.22 | 220,339,813.86 |
| 加:营业外收入 | 1,181,427.54 | 598,027.08 | 476,325.73 | 432,275.26 |
| 减:营业外支出 | 583,373.73 | 286,452.02 | 1,084,553.34 | 606,166.98 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 8,504,332.32 | 3,119,219.51 | 186,125,825.61 | 220,165,922.14 |
| 减:所得税费用 | 337,211.53 | -1,232,715.6 | 20,359,839.81 | 25,048,367.71 |
| 六、净利润 | 8,167,120.79 | 4,351,935.11 | 165,765,985.8 | 195,117,554.43 |
| 持续经营净利润 | 8,167,120.79 | 4,351,935.11 | 165,765,985.8 | 195,117,554.43 |
| 归属于母公司股东的净利润 | 8,167,120.79 | 4,351,935.11 | 165,765,985.8 | 195,117,554.43 |
| (一)基本每股收益 | 0.02 | 0.01 | 0.41 | 0.49 |
| (二)稀释每股收益 | - | 0 | 0.4 | 0.46 |
| 八、其他综合收益 | 78,993.98 | -135,263.53 | 761,799.6 | 1,332,195.88 |
| 归属于母公司股东的其他综合收益 | 78,993.98 | -135,263.53 | 761,799.6 | 1,332,195.88 |
| 九、综合收益总额 | 8,246,114.77 | 4,216,671.58 | 166,527,785.4 | 196,449,750.31 |
| 归属于母公司股东的综合收益总额 | 8,246,114.77 | 4,216,671.58 | 166,527,785.4 | 196,449,750.31 |
| 公告日期 | 2024-08-30 | 2024-04-29 | 2024-04-25 | 2023-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |